Immunologic risk factors for chronic renal allograft dysfunction

Transplantation

Volumn 71, Issue 11 SUPPL., 2001, Pages

  Paul, L C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ANTIBODY RESPONSE; CONFERENCE PAPER; GLOMERULUS BASEMENT MEMBRANE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNE RESPONSE; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MESANGIUM CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TISSUE INJURY;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; CHRONIC DISEASE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MODELS, ANIMAL; RISK FACTORS;

EID: 0035876749     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
2. Significance of the donor age effect on kidney transplants
3. Increased immunogenicity and cause of graft loss of old donor kidneys
4. Nephron mass as a risk factor for progression of renal disease
5. Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation
6. Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American pediatric renal transplant cooperative study
7. Predictors of chronic rejection in renal transplant recipients
8. Predictors of long-term primary cadaveric renal transplant survival
9. 1/2)
10. Long-term renal allograft survival. Prognostic implication of the timing of acute rejection episodes
11. Early versus late acute renal allograft rejection: Impact on chronic rejection
12. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants
13. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection
14. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients
15. Histological findings in early routine biopsies of stable renal allograft recipients
16. Histopathological findings in well-functioning, long-term renal allografts
17. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant
18. Beneficial effects of treatment of early subclinical rejection: A randomized study
19. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors
20. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study
21. Impact of acute rejection and early allograft function on renal allograft survival
22. Clinical correlations of cyclosporine-specific and -nonspecific assays in stable renal transplants, acute rejection, and cyclosporine nephrotoxicity
23. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations
24. Contribution of acute rejection to renal allograft loss from chronic rejection
25. A study of treatment compliance following kidney transplantation
26. Compliance with cyclosporine in adolescent renal transplant recipients
27. The UNOS scientific renal transplant registryten years of kidney transplants. Terasaki, 1997 #783; Smits, 1997 #784; Opelz, 1995 #785
28. Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival
29. The impact of HLA matching on graft survival and on sensitization after a failed transplant - Evidence that failure of poorly matched renal transplants does not result in increased sensitization
30. Cellular immunology markers posttransplantation: Predictive of long-term graft outcome
31. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction
32. Sharing crossreactive groups of MHC class I improves long-term graft survival
33. Donor-specific IgG antibody and the chronic rejection of human renal allografts
34. Living donor transplants
35. Soluble HLA and anti-idiotypic antibodies in transplantation: Modulation of anti-HLA antibodies by soluble HLA antigens from the graft and anti-idiotypic antibodies in renal and cardiac allograft recipients
36. Soluble HLA BLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients
37. The role of anti-HLA antibodies in heart transplantation
38. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies
39. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection
40. Posttransplant anti-HLA antibodies: Risk factor for chronic rejection?
41. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection
42. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation
43. Serological characterization of antibodies eluted from chronically rejected human renal allografts
44. Vascular endothelial alloantigens in renal transplantation
45. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation
46. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: A possible mechanism for transplant atherosclerosis
47. Macrophage infiltration of normal and transplanted heart and kidney tissues in the rat
48. Chronic kidney allograft rejection in the rat
49. Glomerular capillary pressures in long-surviving rat renal allografts
50. Chronic renal allograft rejection in the rat. Transplantation-induced antibodies against basement membrane antigens
51. Chronic allograft nephropathy: An update
52. Antibodies against mesangial cells and their secretory products in chronic renal allograft rejection in the rat
53. Pathophysiology of chronic renal allograft rejection
54. The role of transforming growth factor beta in chronic renal allograft nephropathy